text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 129-06-6 | Product Number: W0005

Warfarin Sodium (contains Isopropyl Alcohol)

Chemical Structure of Warfarin Sodium (contains Isopropyl Alcohol)
×
× Warfarin Sodium (contains Isopropyl Alcohol)

Purity: >98.0%(HPLC)
Synonyms:
  • 3-(α-Acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt (contains Isopropyl Alcohol)
  • 4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt (contains Isopropyl Alcohol)
Product Documents:
SDS | Specifications | C of A & Other Certificates | Analytical Charts

General Information | Specifications & Properties | Safety & Regulations | Applications & Literature

Explanatory notes for this page

5G
€36.00
 4   38  
25G
€135.00
 28   19  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).

Product Number W0005
Purity / Analysis Method >98.0%(HPLC)
Molecular Formula / Molecular Weight C__1__9H__1__5NaO__4 = 330.31 
Physical State (20 deg.C) Solid
Storage Temperature Room Temperature (Recommended in a cool and dark place, <15°C)
Store Under Inert Gas Store under inert gas
Condition to Avoid Air Sensitive
CAS RN 129-06-6
Related CAS RN 81-81-2
Reaxys Registry Number 5469050
PubChem Substance ID 87560363
Merck Index (14) 10038
MDL Number

MFCD00083223
Specifications
Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(Nonaqueous Titration) min. 91.0 %
2-Propanol 7.0 to 9.0 %
Properties (reference)
Solubility (slightly sol. in) Ether, Chloroform
GHS
Pictogram Pictogram Pictogram
Signal Word Danger
Hazard Statements H300 : Fatal if swallowed.
H360 : May damage fertility or the unborn child.
H370 : Causes damage to organs.
H372 : Causes damage to organs through prolonged or repeated exposure.
H373 : May cause damage to organs through prolonged or repeated exposure.
H412 : Harmful to aquatic life with long lasting effects.
Precautionary Statements P260 : Do not breathe dust.
P201 : Obtain special instructions before use.
P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.
P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor.
P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth.
Related Laws:
EC Number 204-929-4
RTECS# GN4725000
Transport Information:
UN Number UN1544
Class 6.1
Packing Group II
HS Number 2932209090
Application
Warfarin Sodium (contains Isopropyl Alcohol) Binding of Warfarin to Human Serum Albumin

Warfarin is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site I on HSA. Those were confirmed using our warfarin sodium with Surface Plasmon Resonance (SPR) and a method using fluorescent probes.
【SPR】
Dose responses of warfarin to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.

W0005

＜Assay condition＞
Sensor Chip: Series S Sensor Chip CM5, Immobilization: HSA (Amine Coupling method), Buffer : 5%DMSO in PBS.

＜Result＞
“Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of warfarin to HSA was confirmed.
【Method using fluorescent probes】
The drug biding site of warfarin was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.

W0005

＜Assay condition＞
Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Warfarin: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).

＜Result＞
As shown in upper diagram, inhibition against binding of dansylamide which is fluorescent probe for site I by warfarin was confirmed. And also, little or extremely weak inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II was confirmed.
In these ways, our warfarin can be used for study of interaction with HSA. Also, DNSA [D5405], DNSG [D5406] and BD140 [D4898] can be used for study of drug binding site on HSA.

References


Application
Reviews of Pharmacology of Warfarin

References


PubMed Literature


Documents

Product Articles
[Product Highlights] Fluorescent Probe for Human Serum Albumin (HSA)-Drug Binding Assay
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and related documentation is no longer provided. Please try a different lot number for this product.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and related documentation is no longer provided. Please try a different lot number for this product.
Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.
Continue Operation
Your session has timed out. You will be redirected to the HOME page.
Close